Psychobehavioural and cognitive adverse events of anti-seizure medications for the treatment of developmental and epileptic encephalopathies

A Strzelczyk, S Schubert-Bast - CNS drugs, 2022 - Springer
The developmental and epileptic encephalopathies encompass a group of rare syndromes
characterised by severe drug-resistant epilepsy with onset in childhood and significant …

Epilepsy in the mTORopathies: opportunities for precision medicine

PB Moloney, GL Cavalleri, N Delanty - Brain communications, 2021 - academic.oup.com
The mechanistic target of rapamycin signalling pathway serves as a ubiquitous regulator of
cell metabolism, growth, proliferation and survival. The main cellular activity of the …

[HTML][HTML] Updated international tuberous sclerosis complex diagnostic criteria and surveillance and management recommendations

H Northrup, ME Aronow, EM Bebin, J Bissler… - Pediatric Neurology, 2021 - Elsevier
Background Tuberous sclerosis complex (TSC) is an autosomal dominant genetic disease
affecting multiple body systems with wide variability in presentation. In 2013, Pediatric …

Tuberous sclerosis: current update

MX Wang, N Segaran, S Bhalla, PJ Pickhardt… - Radiographics, 2021 - pubs.rsna.org
Tuberous sclerosis complex (TSC) is a relatively rare autosomal dominant neurocutaneous
disorder secondary to mutations in the TSC1 or TSC2 tumor suppressor genes. Although …

Role of receptor tyrosine kinases mediated signal transduction pathways in tumor growth and angiogenesis—New insight and futuristic vision

XL Huang, MI Khan, J Wang, R Ali, SW Ali… - International Journal of …, 2021 - Elsevier
In the past two decades, significant progress has been made in the past two decades
towards the understanding of the basic mechanisms underlying cancer growth and …

Review of the treatment options for epilepsy in tuberous sclerosis complex: towards precision medicine

S Schubert-Bast, A Strzelczyk - Therapeutic advances in …, 2021 - journals.sagepub.com
Tuberous sclerosis complex (TSC) is a rare genetic disorder caused by mutations in the
TSC1 or TSC2 genes, which encode proteins that antagonise the mammalian isoform of the …

Towards a treatment for neuroinflammation in epilepsy: interleukin-1 receptor antagonist, anakinra, as a potential treatment in intractable epilepsy

G Yamanaka, Y Ishida, K Kanou, S Suzuki… - International Journal of …, 2021 - mdpi.com
Febrile Infection-Related Epilepsy Syndrome (FIRES) is a unique catastrophic epilepsy
syndrome, and the development of drug-resistant epilepsy (DRE) is inevitable. Recently …

The role of new medical treatments for the management of developmental and epileptic encephalopathies: Novel concepts and results

C Johannessen Landmark, H Potschka, S Auvin… - …, 2021 - Wiley Online Library
Developmental and epileptic encephalopathies (DEEs) are among the most challenging of
all epilepsies to manage, given the exceedingly frequent and often severe seizure types …

Complexity in genetic epilepsies: a comprehensive review

C Rastin, LC Schenkel, B Sadikovic - International Journal of Molecular …, 2023 - mdpi.com
Epilepsy is a highly prevalent neurological disorder, affecting between 5–8 per 1000
individuals and is associated with a lifetime risk of up to 3%. In addition to high incidence …

Treatment of cardiac rhabdomyomas with mTOR inhibitors in children with tuberous sclerosis complex—a systematic review

M Sugalska, A Tomik, S Jóźwiak, B Werner - International Journal of …, 2021 - mdpi.com
Background: Cardiac rhabdomyomas (CRs) are the earliest sign of tuberous sclerosis
complex (TSC). Most of them spontaneously regress after birth. However, multiple and/or …